Biohaven Ltd


Biohaven Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (USD)15.85
  • Today's Change0.44 / 2.86%
  • Shares traded26.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2022 18:10 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company combines a deep understanding of neuroscience, immunology, disease-related biology, advanced chemistry, and expertise in global clinical trials to advance novel therapies for patients. The Company is engaged in delivering new drug approvals for products for diseases such as migraine and schizophrenia, and its research programs, built on a deep understanding of disease-related biology and neuropharmacology, are advancing novel therapies with indications in spinocerebellar ataxia (SCA), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), epilepsy, depression, obsessive-compulsive disorder (OCD) and neuropathic pain. Its Neuroinnovation portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7 ion channels (Kv7), glutamate receptors, myeloperoxidase (MPO), myostatin, and transient receptor potential (TRP) channels.

  • Revenue in USD (TTM)--
  • Net income in USD--
  • Incorporated--
  • Employees--
  • Location
    Biohaven Ltd215 Church StreetNEW HAVEN 06510United StatesUSA
  • Phone+1 (203) 404-0410
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Vericel Corp159.26m-18.10m1.01bn281.00--5.70--6.37-0.3837-0.38373.393.770.67463.605.04566,768.70-7.67-5.85-8.49-6.7466.2965.61-11.36-7.185.54--0.0002--25.7723.49-360.86--41.10--
Kura Oncology Inc0.00-135.47m1.01bn127.00--2.37-----2.03-
USANA Health Sciences, Inc.1.04bn76.88m1.02bn1.98k13.372.4711.260.97923.963.9653.4721.411.832.44--524,742.2013.5520.3418.0627.8680.7382.307.419.982.18--
Lyell Immunopharma Inc39.12m-258.43m1.04bn219.00--1.26--26.51-1.04-1.040.1583.290.036----178,625.60-23.76---25.03-------660.62------0.00--37.31---22.37------
Morphic Holding Inc74.23m-56.07m1.06bn101.00--2.90--14.29-1.53-1.531.959.470.1794--45.26734,940.60-13.55---14.61-------75.53------0.00---55.96---112.32------
Deciphera Pharmaceuticals Inc121.89m-221.39m1.08bn280.00--2.87--8.83-3.46-3.461.825.540.25410.45815.90435,321.40-46.15-44.91-54.79-50.3195.04---181.63-556.775.32--0.00--128.45---12.56--92.99--
Biohaven Ltd-100.00bn-100.00bn1.08bn-------------------------------------------------------80.16------
Arcutis Biotherapeutics Inc725.00k-310.77m1.09bn147.00--4.04--1,510.17-5.89-5.890.01394.450.0016--0.51924,931.97-69.37---74.01--62.90---42,864.14--13.27-34.850.4208-------52.09------
Kiniksa Pharmaceuticals Ltd177.04m142.57m1.10bn215.007.892.857.566.,446.5040.00-58.0645.85-66.5988.67--80.53-1,684.324.02--0.00------2.14--484.21--
Taro Pharmaceutical Industries Ltd.569.41m64.98m1.10bn1.46k17.000.647411.991.941.731.7315.1545.400.25741.442.56391,347.802.943.423.783.9949.5261.5111.4112.783.04--
Opko Health Inc.1.22bn-316.95m1.14bn5.77k--0.6972--0.9309-0.4545-0.45451.762.110.52579.546.45211,580.90-13.62-5.96-15.45-6.8027.9235.98-25.91-12.191.28-22.090.1338--23.649.69-198.55--6.43--
ImmunoGen, Inc.95.61m-201.09m1.14bn106.00--6.39--11.89-0.8151-0.81510.38980.80640.2917--23.42901,952.80-61.35-35.82-91.37-48.56-----210.33-121.91---62.270.00---47.20---213.94------
Madrigal Pharmaceuticals Inc0.00-273.99m1.15bn71.00--107.64-----16.02-
CinCor Pharma Inc0.00-88.09m1.16bn19.00--2.24-----2.38-2.380.0011.860.00----0.00-26.05---26.91-------------14.850.00-------125.89------
Adaptive Biotechnologies Corp168.04m-221.50m1.16bn858.00--2.38--6.91-1.56-1.561.183.410.17913.137.70195,850.80-23.61---26.85--66.87---131.85--5.26--0.00--56.88---41.75------
Data as of Nov 25 2022. Currency figures normalised to Biohaven Ltd's reporting currency: US Dollar USD

Institutional shareholders

14.89%Per cent of shares held by top holders
HolderShares% Held
Suvretta Capital Management LLCas of 21 Oct 20223.84m5.64%
Armistice Capital LLCas of 30 Sep 20221.43m2.10%
Marshall Wace LLPas of 30 Sep 20221.29m1.89%
Millennium Management LLCas of 30 Sep 20221.01m1.49%
Janus Henderson Investors US LLCas of 30 Sep 2022500.80k0.74%
Eventide Asset Management LLCas of 30 Sep 2022495.43k0.73%
SSgA Funds Management, Inc.as of 30 Sep 2022469.54k0.69%
Monashee Investment Management LLCas of 30 Sep 2022400.00k0.59%
Point72 Asset Management LPas of 30 Sep 2022379.90k0.56%
P. Schoenfeld Asset Management LPas of 30 Sep 2022328.00k0.48%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.